News Archives - TinyGems

WednesdayDec 06, 2023 12:32 pm

TinyGemsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Interim Analysis on Global Berubicin Trial Showing Promising Results

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company focused on developing innovative therapies for central nervous system disorders, specifically aggressive brain cancers. In September, the company announced that 200 out of 243 expected patients had been enrolled in its ongoing study evaluating the effectiveness of Berubicin for recurrent glioblastoma (“GBM”), a highly aggressive and incurable form of brain cancer. The critical and adaptive global trial involves multiple centers and is open-label, randomized and controlled, comparing Berubicin to Lomustine - the standard of care - in adult patients with recurrent GBM (“WHO Grade IV”) after standard first-line therapy has failed. The…

MondayDec 04, 2023 1:36 pm

TinyGemsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Announces Strategic Engagement of Basile Law Firm P.C.

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced that it has hired Mark R. Basile, Esq. and his law firm, The Basile Law Firm P.C., to assist the company in reviewing its current fundings and to make recommendations in developing its floorplan for future fundings. “Mullen is committed to full transparency to the public markets. We are making this announcement in an effort to notify our shareholders that we fully intend to take any and all measures necessary to continue our sustainable growth as we move ahead with previously announced strategic initiatives,” said David Michery, CEO…

MondayDec 04, 2023 11:56 am

TinyGemsBreaks — Vision Marine Technologies Inc. (NASDAQ: VMAR), Blue Water Boat Rental Partner in Florida Expansion Offering E-Motion(TM)-Equipped Rentals

Vision Marine Technologies (NASDAQ: VMAR), a global leader and innovator within the performance electric recreational boating industry, is partnering with Blue Water Boat Rental to expand into Riviera Beach, Florida. The company’s new operation is a “key milestone” in a strategic plan to broaden the reach and impact of sustainable electric boating. VMAR’s new Riviera Beach location, which is located near Peanut Island and benefits from Florida's year-round boating climate, is scheduled to open this month. In a first for the company, the location will offer the revolutionary E-Motion(TM) 180E Powertrain System to renters. A leader in internal combustion engine…

TuesdayNov 28, 2023 11:48 am

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Tech Lowers Blood Glucose More Effectively than Branded GLP-1 drug Semaglutide Alone, Study Shows

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is reporting additional positive interim results from its human pilot study evaluating DehydraTECH(TM) technology for the oral delivery of the glucagon-like peptide-1 (“GLP-1”) drug semaglutide, available commercially as Rybelsus(R). According to the report, DehydraTECH-powered semaglutide sustained lower levels of blood glucose from baseline including nearly 10 times lower after 24 hours as well as lower blood-glucose spikes after eating. The company noted that this was the first-ever DehydraTECH test with a “large molecule” drug. According to the report, the study was conducted by a prominent university research center comparing a single…

MondayNov 27, 2023 2:07 pm

TinyGemsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Shown to Improve Oral Performance of GLP-1 Drug in Human Pilot Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced positive interim results from a human pilot study currently underway evaluating DehydraTECH(TM) technology for the oral delivery of the glucagon-like peptide-1 (“GLP-1”) drug semaglutide, which is available commercially in the branded product Rybelsus(R). A prominent university research center is performing the study, comparing a single 7 mg semaglutide dose of a Rybelsus tablet (“control”) to a matching dose from Rybelsus that had been compound formulated in capsule form using DehydraTECH processing technology enhancements (“DehydraTECH GLP-1”). According to the update, blood was examined by a third-party laboratory…

MondayNov 27, 2023 1:18 pm

TinyGemsBreaks – Safety Shot (NASDAQ: SHOT) Begins Scientific Study, Hires Securities Litigation Attorney

Safety Shot (NASDAQ: SHOT), a wellness and functional beverage company, has begun a double-blind, placebo-controlled clinical trial designed to study and evaluate the effects of its flagship product, Safety Shot, on blood and breath alcohol levels. According to the announcement, the company is committed to the scientific development of Safety Shot, the first patented beverage designed to reduce blood alcohol content and boost clarity in order to help people feel better faster. The exclusive nutraceutical functional beverage accelerates the body’s breakdown of alcohol while aiding in recovery and rehydration. The company anticipated having topline data by first quarter 2024. “Recent…

MondayNov 27, 2023 12:48 pm

TinyGemsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Issues Update on CBP Application for Class 1 EV Cargo Vans

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced that the company and Rapid Response Defense Systems (“RRDS”) have filed responses for final ruling and compliance by the U.S. Customs and Border Protection (“CBP”) application for Mullen’s Class 1 EV cargo van. In March 2023, the companies announced a partnership with RRDS, one of the country’s leading small business federal contractors, selecting Mullen as exclusive provider of Class 1 EV cargo vans. On behalf of Mullen, RRDS filed the Ruling Request Application, which details the substantial transformation Mullen completed for the Class 1 EV cargo van to…

TuesdayNov 21, 2023 12:12 pm

TinyGemsBreaks – GEMXX Corp. (GEMZ) Announces Positive Quarterly Revenues, Achievements

GEMXX (OTC: GEMZ), a leader in the ammolite gemstone mine-to-market segment and a partner in Canadian gold exploration Company Crazy Horse Mining Inc. (“CHMI” or “Crazy Horse”), today announced upbeat revenue results and shared company achievements with investors. According to the update, GEMXX performed well in the last quarter and is making significant strides to solidify its strong foundation moving forward in the coming year. “We are pleased with the performance of the company, and we are excited for the anticipated growth in shopping television sales and 2024 production of our gold assets,” said GEMXX CEO Jay Maull. “We look…

ThursdayNov 16, 2023 1:30 pm

TinyGemsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) Partner Receives Key Retail License, Begins Shipping EVs

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, announced that its partner, the Randy Marion Automotive Group (“RMA”), has received its North Carolina license to retail Mullen’s commercial EVs. According to the announcement, this is a required dealer license that allows the auto group to move vehicles to customers. According to RMA officials, the organization is seeing “tremendous interest” in Mullen’s Class 1 and Class 3 vehicles. The new dealer license allows the company to immediately begin delivering Mullen EVs. Beginning Nov. 20, 2023, the company will begin shipping Class 3 vehicles to Adventure Coast Rentals in Tennessee…

ThursdayNov 16, 2023 1:08 pm

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Release Interim Data by Year End for Lead Treatment Candidate Berubicin

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company focused on developing innovative therapies for central nervous system disorders, specifically aggressive brain cancers. The company today announced its confidence in sharing the results from an interim analysis on one of its lead treatment candidates, Berubicin, with the public before the end of the year. Berubicin is a chemotherapy drug that interferes with the DNA of cancer cells to inhibit their growth and potentially shrink tumors. Distinct from other anthracyclines, a clinically trusted class of drugs in use for 60 years against dozens of common cancers, and other traditional chemotherapy drugs, CNS…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (310) 299-1717

Breaks Categories: News